当前位置: 首页 >> 检索结果
122. Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases.
作者: Johannes Schneider-Thoma.;Yikang Zhu.;Mengchang Qin.;Yu Dong.;Shiwei Guan.;Jiaxi Wang.;Jing Tian.;Xiao Lin.;Alessandro Rodolico.;Spyridon Siafis.;Irene Bighelli.;Melanie Wehner.;Christina Veith.;Felix Krayer.;Elfriede Scheuring.;John M Davis.;Josef Priller.;Adriani Nikolakopoulou.;Georgia Salanti.;Chunbo Li.;Stefan Leucht.
来源: Lancet. 2026年407卷10531期876-891页
Antipsychotic drugs are the established treatment for acute schizophrenia but differ in receptor-binding profiles. In 2024, a new-in-class muscarinic receptor agonist (xanomeline-trospium) was licenced, acting upstream of antidopaminergic agents, and providing hope to decrease the adverse effects burden of antipsychotics. We aimed to compare the efficacy and tolerability of antipsychotics by performing network meta-analysis of randomised controlled trials (RCTs).
123. Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study.
作者: Diana L Farmer.;Priyadarsini Kumar.;Elizabeth Reynolds.;Su Yeon Lee.;Amy B Powne.;Christopher D Pivetti.;Marike Zwienenberg.;Amelia S McLennan.;Jan A Nolta.;Erin G Brown.;Payam Saadai.;Shinjiro Hirose.;Aijun Wang.
来源: Lancet. 2026年407卷10531期867-875页
The Management of Myelomeningocele Study (MOMS) trial established the benefit of in-utero repair of myelomeningocele, with a decreased need for ventriculoperitoneal shunt placement. However, although there was some improvement of motor function, over half of the patients were unable to ambulate independently. Live placenta-derived mesenchymal stem cells (PMSCs) seeded on an extracellular matrix have shown promise in rescuing neurological function in the fetal ovine model of myelomeningocele. We aimed to evaluate the safety of this novel, living, stem cell product to augment the prenatal repair of myelomeningocele.
124. Survivorship of modern total hip replacement to 30 years: systematic review, meta-analysis, and extrapolation of global joint registry data.
作者: Veronica Pentland.;Zoe Thompson.;Alimu Dayimu.;Nikos Demiris.;Eric Bohm.;David Campbell.;Erik Lenguerrand.;Anne Marie Fenstad.;Ove Nord Furnes.;Nils Hailer.;Gaeme Hoit.;Johan Kärrholm.;Torbj Rn Berge Kristensen.;Keijo Mäkelä.;S Ren Overgaard.;Elizabeth Paxton.;Heather Prentice.;Bheeshma Ravi.;Mike Reed.;Ola Rolfson.;Claus Varnum.;Tommi Viitanen.;James P Waddell.;Michael Whitehouse.;Amir Khoshbin.;Amit Atrey.
来源: Lancet. 2026年407卷10531期855-866页
Total hip replacement is a successful operation that aims to restore function and quality of life to millions of people globally. Knowing how long a total hip replacement might last is important for patients, surgeons, and health-care institutions for planning and resource allocation. Over the past 20 years, the use of contemporary bearing surfaces for total hip replacement has substantially altered implant wear and, possibly, longevity. To date, there has been no large-scale study that examines survivorship of these modern implants. We aimed to determine the survivorship of contemporary total hip replacements and bearing materials.
|